Epitalon vs Lanreotide
Overview
Epitalon is primarily a anti-aging & longevity peptide, while Lanreotide is used for hormonal.
This page compares Epitalon and Lanreotide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Epitalon | Lanreotide | |
|---|---|---|
| Category | Anti-aging & Longevity | Hormonal |
| Regulatory status (US) | Compounding (Rx) — Apr 2026 | FDA approved |
| Typical dosage | 5-10 mg | 60-120 mg |
| Frequency | cycle | every 4 weeks |
| Reported benefits | Areas studied (research-reported, not established efficacy): telomerase activation and telomere elongation in human cell lines (PMID 12937682; DOI 10.1007/s10522-025-10315-x); increased melatonin synthesis and circadian effects in a small human study; lower overall and cardiovascular mortality in a 12-15 year single-lab trial that used pineal extract (epithalamin), not synthetic AEDG (PMID 17426848, 22451889). No independent multi-center RCTs; not FDA-approved. | suppression of excess growth hormone and IGF-1 in acromegaly, improved progression-free survival in GEP-NETs, reduction of carcinoid syndrome symptoms, inhibition of multiple GI and pancreatic hormones |
| Reported side effects | Khavinson-group trials reported no serious adverse events (e.g., n=162 retinitis pigmentosa trial, PMID 12195242), but these are the only controlled safety data and remain unreplicated. Community use reports mild injection-site reactions. Theoretical concern: telomerase activation is a hallmark of most cancers, and a 2025 review (PMC11943447) notes carcinogenic potential is unstudied. No human pharmacokinetic or drug-interaction data. | diarrhea, cholelithiasis, abdominal pain, hyperglycemia, bradycardia, injection site reactions, nausea, hypertension, headache, thyroid function decreases |
Key differences
Primary use. Epitalon is categorised under Anti-aging & Longevity, while Lanreotide falls under Hormonal. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Epitalon: not FDA-approved; compounding permitted with a prescription as of April 2026. Lanreotide: FDA-approved.
Dosing. Epitalon is typically dosed at 5-10 mg (cycle). Lanreotide is typically dosed at 60-120 mg (every 4 weeks).
Can you stack them?
Some protocols combine peptides, but stacking Epitalon and Lanreotide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Epitalon and Lanreotide?
- Epitalon is primarily a anti-aging & longevity peptide, while Lanreotide is used for hormonal. Epitalon is not FDA-approved; compounding permitted with a prescription (as of April 2026), whereas Lanreotide is FDA-approved for one or more indications.
- What is Epitalon used for?
- Longevity, telomere support.
- What is Lanreotide used for?
- FDA-approved long-acting somatostatin analog for acromegaly, GEP-NETs, and carcinoid syndrome.
- Can you take Epitalon and Lanreotide together?
- Some users combine peptides within a single protocol, but stacking Epitalon and Lanreotide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Epitalon or Lanreotide FDA-approved?
- Epitalon is not FDA-approved; compounding permitted with a prescription (as of April 2026). Lanreotide is FDA-approved for one or more indications.
Read the full articles
- Epitalon — full monograph: mechanism, research, dosing & references
- Lanreotide — full monograph: mechanism, research, dosing & references